Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure

被引：244

作者：

de The, Hugues ^{[1
,2
]}

Pandolfi, Pier Paolo ^{[3
]}

Chen, Zhu ^{[4
]}

机构：

[1] PSL Res Univ, Chaire Oncol Cellulaire & Mol, Coll France, Paris, France

[2] Univ Paris Diderot, CNRS UMR 7212, Sorbonne Paris Cite, Hop St Louis,INSERM UMR 944, Paris, France

[3] Harvard Med Sch, Canc Res Inst, Beth Israel Deaconess Canc Ctr, Dept Pathol & Med,Beth Israel Deaconess Med Ctr, Boston, MA USA

[4] Shanghai Jiao Tong Univ, Shanghai Inst Hematol, Ruijin Hosp, Sch Med, Shanghai 200025, Peoples R China

来源：

CANCER CELL | 2017年 / 32卷 / 05期

关键词：

TRANS-RETINOIC ACID; PML-RAR-ALPHA; ARSENIC TRIOXIDE AS2O3; TUMOR-SUPPRESSOR PML; FOLLOW-UP; IN-VITRO; T(15-17) TRANSLOCATION; CELLULAR SENESCENCE; GROWTH-SUPPRESSOR; INTERFERON-ALPHA;

D O I：

10.1016/j.ccell.2017.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent clinical trials have demonstrated that the immense majority of acute promyelocytic leukemia (APL) patients can be definitively cured by the combination of two targeted therapies: retinoic acid (RA) and arsenic. Mouse models have provided unexpected insights into the mechanisms involved. Restoration of PML nuclear bodies upon RA- and/or arsenic-initiated PML/RARA degradation is essential, while RA-triggered transcriptional activation is dispensable for APL eradication. Mutations of the arsenic-binding site of PML/RARA, but also PML, have been detected in therapy-resistant patients, demonstrating the key role of PML in APL cure. PML nuclear bodies are druggable and could be harnessed in other conditions.

引用

页码：552 / 560

页数：9

共 130 条

[51] Positive Role of Promyelocytic Leukemia Protein in Type I Interferon Response and Its Regulation by Human Cytomegalovirus [J].

Kim, Young-Eui ;

Ahn, Jin-Hyun .

PLOS PATHOGENS, 2015, 11 (03) :1-24

[52] Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARα fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient [J].

Koken, MHM ;

Daniel, MT ;

Gianni, M ;

Zelent, A ;

Licht, J ;

Buzyn, A ;

Minard, P ;

Degos, L ;

Varet, B ;

de Thé, H .

ONCOGENE, 1999, 18 (04) :1113-1118

[53]

KOKEN MHM, 1995, ONCOGENE, V10, P1315

[54] The PML domain of PML-RARα blocks senescence to promote leukemia [J].

Korf, Katharina ;

Wodrich, Harald ;

Haschke, Alexander ;

Ocampo, Corinne ;

Harder, Lena ;

Gieseke, Friederike ;

Pollmann, Annika ;

Dierck, Kevin ;

Prall, Sebastian ;

Staege, Hannah ;

Ma, Hui ;

Horstmann, Martin A. ;

Evans, Ronald M. ;

Sternsdorf, Thomas .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (33) :12133-12138

[55] Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS [J].

Kroenke, Jan ;

Fink, Emma C. ;

Hollenbach, Paul W. ;

MacBeth, Kyle J. ;

Hurst, Slater N. ;

Udeshi, Namrata D. ;

Chamberlain, Philip P. ;

Mani, D. R. ;

Man, Hon Wah ;

Gandhi, Anita K. ;

Svinkina, Tanya ;

Schneider, Rebekka K. ;

McConkey, Marie ;

Jaeras, Marcus ;

Griffiths, Elizabeth ;

Wetzler, Meir ;

Bullinger, Lars ;

Cathers, Brian E. ;

Carr, Steven A. ;

Chopra, Rajesh ;

Ebert, Benjamin L. .

NATURE, 2015, 523 (7559) :183-U102

[56] Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells [J].

Kroenke, Jan ;

Udeshi, Namrata D. ;

Narla, Anupama ;

Grauman, Peter ;

Hurst, Slater N. ;

McConkey, Marie ;

Svinkina, Tanya ;

Heckl, Dirk ;

Comer, Eamon ;

Li, Xiaoyu ;

Ciarlo, Christie ;

Hartman, Emily ;

Munshi, Nikhil ;

Schenone, Monica ;

Schreiber, Stuart L. ;

Carr, Steven A. ;

Ebert, Benjamin L. .

SCIENCE, 2014, 343 (6168) :301-305

[57] Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia [J].

Lallemand-Breitenbach, V ;

Guillemin, MC ;

Janin, A ;

Daniel, MT ;

Degos, L ;

Kogan, SC ;

Bishop, JM ;

de Thé, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (07) :1043-1052

[58] Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor α degradation [J].

Lallemand-Breitenbach, V ;

Zhu, J ;

Puvion, F ;

Koken, M ;

Honoré, N ;

Doubeikovsky, A ;

Duprez, E ;

Pandolfi, PP ;

Puvion, E ;

Freemont, P ;

de Thé, H .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (12) :1361-1371

[59] Arsenic degrades PML or PML - RARα through a SUMO-triggered RNF4/ubiquitin-mediated pathway [J].

Lallemand-Breitenbach, Valerie ;

Jeanne, Marion ;

Benhenda, Shirine ;

Nasr, Rihab ;

Lei, Ming ;

Peres, Laurent ;

Zhou, Jun ;

Zhu, Jun ;

Raught, Brian ;

de The, Hugues .

NATURE CELL BIOLOGY, 2008, 10 (05) :547-555

[60] PML Nuclear Bodies [J].

Lallemand-Breitenbach, Valerie ;

de The, Hugues .

COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY, 2010, 2 (05) :a000661

← 1 2 3 4 5 6 7 8 9 10 →